TLX592

TLX592 is an investigational targeted alpha therapy (TAT) for prostate cancer that utilizes Telix Pharmaceuticals' proprietary RADmAb® engineered antibody technology. It targets prostate-specific membrane antigen (PSMA), which is almost ubiquitously expressed by prostate cancer cells. The RADmAb® approach accelerates blood clearance and reduces bone marrow residence time compared to standard monoclonal antibodies, while maintaining target selectivity, internalization, and retention. These characteristics make it particularly suitable for use with alpha-emitting radioisotopes like actinium-225 (225Ac). TLX592 is being developed for both early metastatic prostate cancer and late-stage patients who are no longer responding to lutetium therapy.

Other names

Actinium-225 TLX592Actinium225 TLX592Actinium 225 TLX592225Ac-RAD-AR